Negotiated prices for Kisqali and Verzenio, which the agency said cost Medicare over $1 billion in a year, would become effective starting 2028.

The FDA halted clinical trials of two gene therapies on account of a tumor found in a Hurler syndrome patient who had received RGX-111.

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in ...

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a ...

Researchers will evaluate the IL1RAP-targeted nadunolimab with a checkpoint inhibitor in up to 24 metastatic microsatellite stable colorectal cancer patients.

The FDA had placed a clinical hold on Phase III trials of nex-z in ATTR-PN and ATTR-CM after a patient experienced a serious adverse event and died.

Research conducted by Gustave Roussy will help StarkAge move STX-01, an antibody-drug conjugate targeting senescent cells, toward clinical trials.

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...

The US regulator expects to issue a decision on Eisai's application for Leqembi Iqlik, which it has granted priority review, by May 24.

The NHS will collect information from patients about 120 different genetic abnormalities to fast-track access to screening.

Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.